360 related articles for article (PubMed ID: 28618015)
1. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
[TBL] [Abstract][Full Text] [Related]
2. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
Andersen ES; Rødgaard-Hansen S; Moessner B; Christensen PB; Møller HJ; Weis N
Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
[TBL] [Abstract][Full Text] [Related]
3. Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose.
Siggaard CB; Kazankov K; Rødgaard-Hansen S; Møller HJ; Donnelly MC; Simpson KJ; Grønbaek H
Scand J Gastroenterol; 2019 May; 54(5):623-632. PubMed ID: 31067143
[TBL] [Abstract][Full Text] [Related]
4. Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients.
Kjærgaard AG; Rødgaard-Hansen S; Dige A; Krog J; Møller HJ; Tønnesen E
PLoS One; 2014; 9(3):e92331. PubMed ID: 24637679
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
[TBL] [Abstract][Full Text] [Related]
7. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
Kimer N; Gudmann NS; Pedersen JS; Møller S; Nielsen MJ; Leeming DJ; Karsdal MA; Møller HJ; Bendtsen F; Grønbæk H
PLoS One; 2018; 13(9):e0203200. PubMed ID: 30183743
[TBL] [Abstract][Full Text] [Related]
8. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
[TBL] [Abstract][Full Text] [Related]
9. The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma.
Andersen MN; Andersen NF; Rødgaard-Hansen S; Hokland M; Abildgaard N; Møller HJ
Leuk Res; 2015 Sep; 39(9):971-5. PubMed ID: 26169445
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation.
Rainer F; Horvath A; Sandahl TD; Leber B; Schmerboeck B; Blesl A; Groselj-Strele A; Stauber RE; Fickert P; Stiegler P; Møller HJ; Grønbaek H; Stadlbauer V
Aliment Pharmacol Ther; 2018 Mar; 47(5):657-664. PubMed ID: 29266346
[TBL] [Abstract][Full Text] [Related]
11. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
12. Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure.
Ye H; Wang LY; Zhao J; Wang K
World J Gastroenterol; 2013 May; 19(18):2818-25. PubMed ID: 23687420
[TBL] [Abstract][Full Text] [Related]
13. Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis.
Heftdal LD; Loft AG; Hendricks O; Ashouri Christiansen A; Schiøttz-Christensen B; Arnbak B; Jurik AG; Østgård R; Winding Deleuran B; Møller HJ; Greisen SR
Scand J Clin Lab Invest; 2018 Oct; 78(6):483-489. PubMed ID: 30176763
[TBL] [Abstract][Full Text] [Related]
14. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
Grønbæk H; Rødgaard-Hansen S; Aagaard NK; Arroyo V; Moestrup SK; Garcia E; Solà E; Domenicali M; Piano S; Vilstrup H; Møller HJ;
J Hepatol; 2016 Apr; 64(4):813-22. PubMed ID: 26639396
[TBL] [Abstract][Full Text] [Related]
15. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.
Dultz G; Gerber L; Zeuzem S; Sarrazin C; Waidmann O
J Viral Hepat; 2016 Apr; 23(4):267-73. PubMed ID: 26554542
[TBL] [Abstract][Full Text] [Related]
16. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
Lidofsky A; Holmes JA; Feeney ER; Kruger AJ; Salloum S; Zheng H; Seguin IS; Altinbas A; Masia R; Corey KE; Gustafson JL; Schaefer EA; Hunt PW; Deeks S; Somsouk M; Chew KW; Chung RT; Alatrakchi N
J Infect Dis; 2018 Sep; 218(9):1394-1403. PubMed ID: 29868909
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis.
Bossen L; Rebora P; Bernuzzi F; Jepsen P; Gerussi A; Andreone P; Galli A; Terziroli B; Alvaro D; Labbadia G; Aloise C; Baiocchi L; Giannini E; Abenavoli L; Toniutto P; Marra F; Marzioni M; Niro G; Floreani A; Møller HJ; Valsecchi MG; Carbone M; Grønbaek H; Invernizzi P
Liver Int; 2020 Jun; 40(6):1408-1414. PubMed ID: 32279422
[TBL] [Abstract][Full Text] [Related]
18. The macrophage activation marker sMR as a diagnostic and prognostic marker in patients with acute infectious disease with or without sepsis.
Marie Relster M; Gaini S; Møller HJ; Johansen IS; Pedersen C
Scand J Clin Lab Invest; 2018 May; 78(3):180-186. PubMed ID: 29383956
[TBL] [Abstract][Full Text] [Related]
19. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
20. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
